O

Orange County Retina Medical Group | Santa Ana, CA

Research site

(Unclaimed)

Location

999 North Tustin Avenue Suite 17, Santa Ana, California, United States of America

Site insights

Top conditions

Top treatments

KSI-301

APL-2

Triamcinolone Acetonide

Aflibercept

ABP 938

Dexamethasone Phosphate

Bevasiranib

Abicipar Pegol

Pegcetacoplan

Eylea®

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 22 total trials

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting

Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: PEGCETACOPLAN (APL-2)

Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling

Wet Age-related Macular Degeneration

Wet AMD

Genetic: RGX-314

Biological: Ranibizumab (LUCENTIS®)

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling

Wet Age-related Macular Degeneration

WetAMD

Genetic: RGX-314 Dose 2

Biological: Aflibercept (EYLEA®)